Premium
ETS transcription factors as emerging drug targets in cancer
Author(s) -
Hsing Michael,
Wang Yuzhuo,
Rennie Paul S.,
Cox Michael E.,
Cherkasov Artem
Publication year - 2020
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21575
Subject(s) - ets transcription factor family , prostate cancer , transcription factor , drug discovery , context (archaeology) , cancer , biology , computational biology , drug , drug target , protein family , bioinformatics , cancer research , medicine , genetics , pharmacology , gene , paleontology
The ETS family of proteins consists of 28 transcription factors, many of which have been implicated in development and progression of a variety of cancers. While one family member, ERG, has been rigorously studied in the context of prostate cancer where it plays a critical role, other ETS factors keep emerging as potential hallmark oncodrivers. In recent years, numerous studies have reported initial discoveries of small molecule inhibitors of ETS proteins and opened novel avenues for ETS‐directed cancer therapies. This review summarizes the state of the art data on therapeutic targeting of ETS family members and highlights the corresponding drug discovery strategies.